The federal government recently capped insulin prices at $35 a month for Medicare Part D, and drugmakers that increase insulin costs faster than inflation rates can be hit with tax penalties. Dr. Rose said these efforts are “welcome news” but come with a catch for the 37 million Americans with Type 2 diabetes.
“Of all diabetes medications, insulin carries the highest risk of causing dangerously low blood sugar,” Dr. Rose wrote. “Although insulin is excellent at tamping down high blood sugar — the hallmark of diabetes and the driver of some of its complications — it is not as impressive as other medications at mitigating the most deadly and debilitating consequences of the disease: heart attacks, kidney disease and heart failure.”
Because insulin prices and efficacy levels are decreasing, “doctors are forced daily to decide between the best medication for our patients and the medication that our patients can afford,” Dr. Rose wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
